Treatment of patients with Waldenström macroglobulinaemia: clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.
Autor: | Talaulikar D; ACT Pathology, Canberra Hospital, Canberra, Australian Capital Territory, Australia.; College of Health and Medicine, Australian National University, Australian Capital Territory, Canberra, Australia., Joshua D; Institute of Haematology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia., Ho PJ; Institute of Haematology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.; University of Sydney, Sydney, New South Wales, Australia., Gibson J; Institute of Haematology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.; University of Sydney, Sydney, New South Wales, Australia., Quach H; St Vincent's Hospital, Melbourne, Victoria, Australia.; Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Victoria, Australia., Gibbs S; Department of Haematology, Eastern Health, Melbourne, Victoria, Australia.; Eastern Clinical Research Unit, Monash University, Melbourne, Victoria, Australia., Ling S; Liverpool Hospital, Sydney, New South Wales, Australia., Ward C; Royal North Shore Hospital, Sydney, New South Wales, Australia., Augustson BM; Department of Haematology, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia., Trotman J; University of Sydney, Sydney, New South Wales, Australia.; Concord Repatriation General Hospital, Sydney, New South Wales, Australia., Harrison SJ; Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia, Australia., Tam CS; Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Victoria, Australia.; Alfred Hospital, Melbourne, Australia, Australia.; Central Clinical School, Monash University, Melbourne, Australia, Australia. |
---|---|
Jazyk: | angličtina |
Zdroj: | Internal medicine journal [Intern Med J] 2023 Apr; Vol. 53 (4), pp. 599-609. Date of Electronic Publication: 2023 Apr 05. |
DOI: | 10.1111/imj.15980 |
Abstrakt: | Waldenström macroglobulinaemia (WM) is an indolent B-cell malignancy characterised by the presence of IgM paraprotein, bone marrow infiltration by clonal small B lymphocytes with plasmacytic differentiation and the MYD88 L265P mutation in >90% of cases. Traditionally, WM has been treated with chemoimmunotherapy. Recent trials have demonstrated the efficacy and safety of Bruton tyrosine kinase inhibitors in WM, both as monotherapy and in combination with other drugs. There is emerging evidence on the use of other agents including B-cell lymphoma 2 inhibitors and on the treatment of rare presentations of WM. In this update, the Medical and Scientific Advisory Group of Myeloma Australia reviews the available evidence on the treatment of WM since the last publication in 2017 and provides specific recommendations to assist Australian clinicians in the management of this disease. (© 2022 The Authors. Internal Medicine Journal published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Physicians.) |
Databáze: | MEDLINE |
Externí odkaz: |